Trial primary completion date • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
|
PD-L1 expression • MSI-H/dMMR
|
Keytruda (pembrolizumab) • Odomzo (sonidegib)